# Julian R. Molina

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julian-r-molina/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,863 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 56 |
| i10-index | 141 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5038755935 |
| ORCID iD | https://orcid.org/0000-0002-9962-4635 |
| Works | 412 |

## Researcher papers

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials](https://scholariq.org/papers/treatment-related-adverse-events-of-pd-1-and-pd-l1-inhibitors-in-clinical-trials/)
- [Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/small-cell-lung-cancer-version-2-2022-nccn-clinical-practice-guidelines-in/)
- [Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study](https://scholariq.org/papers/efficacy-of-pazopanib-in-progressive-radioiodine-refractory-metastatic/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.